menu
    • menu
    [{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Expanded Collaboration","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Sanofi","amount2":2.2999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":2.2999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Translate Bio","highestDevelopmentStatusID":"2","companyTruncated":"Sanofi \/ Translate Bio"},{"orgOrder":0,"company":"Mutabilis","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"2G-Dabocins","moa":"Diazabicyclooctanes penicillin-binding proteins","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Mutabilis","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Mutabilis \/ Organovo Holdings","highestDevelopmentStatusID":"2","companyTruncated":"Mutabilis \/ Organovo Holdings"},{"orgOrder":0,"company":"Vetophage","sponsor":"Phaxiam Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Vetophage","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vetophage \/ Phaxiam Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Vetophage \/ Phaxiam Therapeutics"},{"orgOrder":0,"company":"Iktos","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Iktos","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iktos \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"2","companyTruncated":"Iktos \/ Medicines for Malaria Venture"}]

    Find Novel Drugs for Infections and Infectious Diseases under Discovery in FRANCE

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : mRNA Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Sponsor : Sanofi

                            Deal Size : $2,300.0 million

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas

                            Details : The two companies will build upon their existing collaboration to pursue novel mRNA vaccines aimed at broadly addressing current and future infectious diseases.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : $425.0 million

                            June 23, 2020

                            Lead Product(s) : mRNA Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Sponsor : Sanofi

                            Deal Size : $2,300.0 million

                            Deal Type : Expanded Collaboration

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vetophage

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Vetophage

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Sponsor : Phaxiam Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration

                            Details : The agreement aims to combine company's expertise in the research of new phages and phage-derived proteins (endolysins) in the fight against antimicrobial resistance.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 03, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Sponsor : Phaxiam Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Iktos

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Iktos

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Sponsor : Medicines for Malaria Venture

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Iktos Partners with Medicines for Malaria Venture in Anti-Malarial Drug Discovery

                            Details : Under the collaboration agreement, Iktos will apply its new ‘DockAI’ technology to expedite the discovery of novel antimalarial drug candidates.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 23, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Sponsor : Medicines for Malaria Venture

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Mutabilis

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Mutabilis

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2G-Dabocins

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Sponsor : Organovo Holdings

                            Deal Size : $11.9 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Novo Holdings REPAIR Impact Fund Invests USD 12 Million in Mutabilis and IBT Vaccines and Provides Strategic U...

                            Details : This investment will allow the Mutabilis to accelerate its 2G-Dabocins program, a wide spectrum Gram-negative anti-infective agent, which is currently undergoing lead optimization.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 06, 2020

                            Lead Product(s) : 2G-Dabocins

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Sponsor : Organovo Holdings

                            Deal Size : $11.9 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth